Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C

Autor: Mireia Miquel, Meritxell Casas, Joao Pedro da Costa, Xavier Calvet, Oliver Valero, Teresa Monllor, Blai Dalmau, Isabel Parra, Jordi Sánchez-Delgado, Angelina Dosal, Mercedes Vergara, Núria Rudi, Marta Gallach, Meritxell Sanchez-Lloansí
Jazyk: angličtina
Rok vydání: 2018
Předmět:
Questionnaires
RNA viruses
Male
Cirrhosis
Sustained Virologic Response
Comorbidity
Hepacivirus
Anxiety
Patient Health Questionnaire
Hospital Anxiety and Depression Scale
0302 clinical medicine
Medicine and Health Sciences
Medicine
030212 general & internal medicine
Prospective Studies
Depression (differential diagnoses)
Pathology and laboratory medicine
Multidisciplinary
Pharmaceutics
Antimicrobials
Hepatitis C virus
Depression
Liver Diseases
Mental Disorders
Drugs
Hepatitis C
Medical microbiology
Middle Aged
Antivirals
Research Design
Viruses
030211 gastroenterology & hepatology
Female
medicine.symptom
Pathogens
Research Article
medicine.medical_specialty
Science
Gastroenterology and Hepatology
Research and Analysis Methods
Microbiology
Antiviral Agents
03 medical and health sciences
Pharmacotherapy
Chronic hepatitis
Drug Therapy
Internal medicine
Microbial Control
Virology
Mental Health and Psychiatry
Humans
Aged
Pharmacology
Survey Research
Biology and life sciences
Flaviviruses
business.industry
Mood Disorders
Organisms
Viral pathogens
Repeated measures design
Correction
Hepatitis C
Chronic
medicine.disease
Fibrosis
Hepatitis viruses
Microbial pathogens
business
Developmental Biology
Zdroj: PLoS ONE
PLoS ONE, Vol 13, Iss 12, p e0208112 (2018)
Popis: Background and aim Treatment of hepatitis C with direct-acting antiviral agents (DAA) has few side effects. Although pivotal studies suggested that DAA were safe in patients with psychiatric diseases who could not be treated with previous antiviral therapies, their effects on anxiety and depression have not yet been analysed in clinical practice. The aim of our study was to analyse anxiety and depression in the setting of DAA treatment in a clinical practice series. Methods All patients starting DAA treatment between November 1, 2014 and October 31, 2015 were eligible. Patients completed the Hospital Anxiety and Depression scale at different times during treatment. The results were plotted on line graphs and evaluated using a linear regression model with repeated measures. Results One hundred and forty-five patients were included (11% with major psychiatric disorders; 32% on psychiatric treatment). Sustained virologic response (SVR) was achieved in 97.3% of cases. Anxiety and depression measures did not differ between time points. No differences between patients on psychiatric treatment or with advanced fibrosis or cirrhosis were found at any time point analysed. Conclusion DAA treatment had no impact on anxiety or depression during or after chronic hepatitis C infection treatment, even in high-risk patients with major psychiatric disorders.
Databáze: OpenAIRE
Externí odkaz: